ATE447610T1 - Kristalliner vap-1 und verwendung - Google Patents

Kristalliner vap-1 und verwendung

Info

Publication number
ATE447610T1
ATE447610T1 AT04734701T AT04734701T ATE447610T1 AT E447610 T1 ATE447610 T1 AT E447610T1 AT 04734701 T AT04734701 T AT 04734701T AT 04734701 T AT04734701 T AT 04734701T AT E447610 T1 ATE447610 T1 AT E447610T1
Authority
AT
Austria
Prior art keywords
vap
crystalline
usage
present
crystalline vap
Prior art date
Application number
AT04734701T
Other languages
English (en)
Inventor
Tiina Salminen
Tomi Airenne
Mark Johnson
Heidi Kidron
Yvonne Nymalm-Rejstroem
Annu Soederholm
David Smith
Marjo Pihlavisto
Lenita Viitanen
Olli Pentikaeinen
Tommi Nyroenen
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030786A external-priority patent/FI20030786A0/fi
Priority claimed from FI20040271A external-priority patent/FI20040271A0/fi
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Application granted granted Critical
Publication of ATE447610T1 publication Critical patent/ATE447610T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
AT04734701T 2003-05-26 2004-05-25 Kristalliner vap-1 und verwendung ATE447610T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030786A FI20030786A0 (fi) 2003-05-26 2003-05-26 VAP-1:n uusi käyttö
FI20040271A FI20040271A0 (fi) 2004-02-20 2004-02-20 Kiteinen VAP-1 ja sen käyttö
PCT/FI2004/000318 WO2004104191A1 (en) 2003-05-26 2004-05-25 Crystalline vap-1 and uses thereof

Publications (1)

Publication Number Publication Date
ATE447610T1 true ATE447610T1 (de) 2009-11-15

Family

ID=33477699

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04734701T ATE447610T1 (de) 2003-05-26 2004-05-25 Kristalliner vap-1 und verwendung

Country Status (12)

Country Link
US (2) US7499847B2 (de)
EP (1) EP1633861B1 (de)
JP (1) JP2007509605A (de)
AT (1) ATE447610T1 (de)
AU (1) AU2004241060B2 (de)
CA (1) CA2526675A1 (de)
DE (1) DE602004023939D1 (de)
DK (1) DK1633861T3 (de)
ES (1) ES2335769T3 (de)
HK (1) HK1086591A1 (de)
NZ (1) NZ543430A (de)
WO (1) WO2004104191A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
EP2084518A4 (de) * 2007-01-12 2014-04-16 Veronica James Biometrische diagnose
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
CA3007768A1 (en) 2015-12-07 2017-06-15 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580780A (en) 1992-06-09 1996-12-03 Jalkanen; Sirpa Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
PL192459B1 (pl) 1997-05-23 2006-10-31 Biotie Therapies Corp Sposób utleniania aminy, sposób zahamowania aktywności oksydazy aminowej i sposoby manipulowania wiązaniem limfocytów z komórkami śródbłonka
NZ505914A (en) * 1998-02-06 2004-03-26 Ilexus Pty Ltd Three-dimensional structures and models of fc receptors and uses thereof
WO2002002541A2 (en) 2000-07-05 2002-01-10 Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
US7167801B2 (en) * 2001-07-12 2007-01-23 Boehringer Ingelheim (Canada) Ltd. Method of identifying potential inhibitors of human papillomavirus protein E2 using x-ray atomic coordinates
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset

Also Published As

Publication number Publication date
DK1633861T3 (da) 2010-03-22
WO2004104191A1 (en) 2004-12-02
DE602004023939D1 (de) 2009-12-17
US20110021760A1 (en) 2011-01-27
HK1086591A1 (en) 2006-09-22
AU2004241060A1 (en) 2004-12-02
US20070093646A1 (en) 2007-04-26
CA2526675A1 (en) 2004-12-02
JP2007509605A (ja) 2007-04-19
US7499847B2 (en) 2009-03-03
EP1633861B1 (de) 2009-11-04
AU2004241060B2 (en) 2009-07-23
WO2004104191A8 (en) 2006-08-17
NZ543430A (en) 2008-06-30
EP1633861A1 (de) 2006-03-15
ES2335769T3 (es) 2010-04-05

Similar Documents

Publication Publication Date Title
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
ATE471324T1 (de) Triazolophthalazine
ATE552834T1 (de) Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
NO20055741D0 (no) Nye kjemiske forbindelser
DE602005025878D1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
CY1109740T1 (el) Νεα μεθοδος συνθεσης παραγωγων της 1,3,4,5 -τετραϋδρο-2η- 3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης της σε ενα φαρμακευτικως αποδεκτο οξυ
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
HK1086591A1 (en) Crystalline vap-1 and uses thereof
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
RS20070095A (en) Alkyliden-tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents
ATE443044T1 (de) Tace inhibitoren
DE10342670A1 (de) Isoliertes Photoprotein mtClytin, sowie dessen Verwendung
DE602004027086D1 (de) Klassifizierung von kolonkrebs
ATE390427T1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
DE50308032D1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
DE502004002460D1 (de) Verwendung von copolymerisaten als hilfsmittel für die lederherstellung
ATA18172002A (de) Rahmen für sessel, insbesondere von sesselliften
DE60328621D1 (de) Cyclooct-(en-)yl-derivate zur verwendung als duftstoffe
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1633861

Country of ref document: EP

REN Ceased due to non-payment of the annual fee